Both in R&D — Physical & Biological Sciences
IB Acquisition vs bioAffinity Technologies
Over the past year IBAC returned +3.7% and BIAF returned −90.3%; their daily moves had a correlation of 0.02.
IBAC +3.7% BIAF −90.3%Growth of $1, one year, split-adjusted
| Metric | IBAC | BIAF |
|---|---|---|
| Price | $10.81 | $2.65 |
| Market cap | $54.1M | $1.6M |
| Today | −0.46% | −9.56% |
| 1 month | −0.6% | −57.0% |
| 6 months | −0.2% | −91.7% |
| Year to date | +3.0% | −85.0% |
| 1 year | — | −91.5% |
| Revenue growth (YoY) | — | +19.0% |
| Gross margin | — | 100.0% |
| Net margin | — | −222.8% |
| P/E (TTM) | — | — |
| Price / sales | — | 0.3× |
| Net cash | — | $1.8M |
| Dividend yield | — | — |
| Volatility (60d) | 20.1% | 826.2% |
| Short % of float | 0.3% | 11.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).